Qingdao Haier Biomedical Co (688139) Fair Value & Analysis
Healthcare · CN · Market cap 8.6B CNY
Fair value as of: Jun 24, 2026
Analysis
Qingdao Haier Biomedical Co (688139) currently trades at ¥26.24, while our model-based Fair Value estimate is ¥15.33 — implying the stock looks roughly 41.6% overvalued today. We read business quality at 89/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Qingdao Haier Biomedical Co.,Ltd engages in the research and development, manufacture, marketing, and sale of low temperature storage equipment for biomedical samples in China and internationally. The company offers ULT freezers, pharmacy refrigerators, freezers, automatic storage solutions, cryogenics, active temperature controlled RKN containers, and RTMD products; and CO2 incubation, standard incubators, biological safety cabinets, clean benches and laminar, and sterilization products. It also provides floor standing, benchtop refrigerated, and benchtop centrifuges; intelligent pharmacy automation and RFID pharmacy products; blood bank refrigerators, blood component management products, blood plasma freezers, and transport coolers; and vaccine storage, cold/freezer room, medical waste disposal equipment, and other products. In addition, the company offers freezer and controlled rate freezers; microwave digestion system; UV visible spectrophotometer and total organic carbon analyz…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Qingdao Haier Biomedical Co (688139) undervalued?
What is the fair value of 688139?
What is the quality score of 688139?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.